U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3 |
| |
| Authors: | Ekwere T Ifon Alan LY Pang Warren Johnson Kathleen Cashman Sharon Zimmerman Sumitra Muralidhar Wai-Yee Chan John Casey and Leonard Jason Rosenthal |
| |
| Affiliation: | (1) Department of Microbiology and Immunology, Georgetown University Medical Center, 3900 Reservoir Road, NW Washington, D.C. 20057, USA;(2) Laboratory of Clinical Genomics, NICHD, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA;(3) Department of Pediatrics, Georgetown University Medical Center, 3800 Reservoir Road, NW Washington, D.C. 20057, USA;(4) Department of Cell Biology, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, D.C. 20057;(5) Department of Biochemistry & Molecular Biology, Georgetown University Medical Center, 3800 Reservoir Road, NW Washington, D.C. 20057, USA |
| |
| Abstract: | Background Insensitivity of advanced-stage prostate cancer to androgen ablation therapy is a serious problem in clinical practice because
it is associated with aggressive progression and poor prognosis. Targeted therapeutic drug discovery efforts are thwarted
by lack of adequate knowledge of gene(s) associated with prostate tumorigenesis. Therefore there is the need for studies to
provide leads to targeted intervention measures. Here we propose that stable expression of U94, a tumor suppressor gene encoded by human herpesvirus 6A (HHV-6A), could alter gene expression and thereby inhibit the tumorigenicity
of PC3 cell line. Microarray gene expression profiling on U94 recombinant PC3 cell line could reveal genes that would elucidate prostate cancer biology, and hopefully identify potential
therapeutic targets. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
